Coherus Oncology, Inc. Common Stock (CHRS)

Price$1.57

Value ScoreB

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)28.62%

Price vs S&P 500 (4W)-16.64%

VGM Score58.00

Market Capitalization$245.26M

P/E Ratio (Annual)1.46x

All Metrics

Book Value / Share (Quarterly)$0.51

P/TBV (Annual)11.62x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-41.53%

Cash Flow / Share (Quarterly)$-1.11

Price vs S&P 500 (YTD)1.04%

Gross Margin (TTM)68.06%

Net Profit Margin (TTM)397.30%

EPS (TTM)$1.67

10-Day Avg Trading Volume1.22M

EPS Excl Extra (TTM)$1.67

Revenue Growth (5Y)-38.41%

EPS (Annual)$1.43

ROI (Annual)149.90%

Gross Margin (Annual)67.24%

Net Profit Margin (5Y Avg)18.09%

Cash / Share (Quarterly)$1.08

P/E Basic Excl Extra (TTM)1.32x

Revenue Growth QoQ (YoY)61.99%

EPS Growth (5Y)-1.96%

P/E Normalized (Annual)1.46x

ROA (Last FY)65.04%

Revenue Growth TTM (YoY)-76.26%

EBITD / Share (TTM)$-1.37

ROE (5Y Avg)-127.02%

Operating Margin (TTM)-366.55%

Cash Flow / Share (Annual)$-1.14

P/B Ratio3.12x

P/B Ratio (Quarterly)3.31x

Net Income / Employee (Annual)$1,143,000

EV / Revenue (TTM)3.87x

Net Interest Coverage (TTM)-33.01x

ROA (TTM)50.33%

EV / EBITDA (TTM)3.15x

EPS Incl Extra (Annual)$1.43

Current Ratio (Annual)1.47x

Quick Ratio (Quarterly)1.43x

3-Month Avg Trading Volume1.87M

52-Week Price Return98.25%

P/E Incl Extra (TTM)1.32x

Revenue / Employee (TTM)$318,900

Tangible BV / Share (Quarterly)$0.21

P/S Ratio (Annual)5.82x

Asset Turnover (Annual)0.16x

52-Week High$2.62

Operating Margin (5Y Avg)-158.70%

EPS Excl Extra (Annual)$1.43

Tangible BV CAGR (5Y)-3.76%

26-Week Price Return44.55%

Quick Ratio (Annual)1.36x

13-Week Price Return-5.92%

Total Debt / Equity (Annual)0.84x

Current Ratio (Quarterly)1.56x

Enterprise Value$181.54M

Revenue / Share Growth (5Y)-42.44%

Asset Turnover (TTM)0.13x

Book Value / Share Growth (5Y)2.39%

Revenue / Employee (Annual)$286,900

Inventory Turnover (Annual)0.38x

Pretax Margin (Annual)-434.23%

Cash / Share (Annual)$1.42

3-Month Return Std Dev66.12%

Gross Margin (5Y Avg)52.25%

Net Income / Employee (TTM)$1,267,100

EBITDA CAGR (5Y)-13.04%

ROE (Last FY)275.39%

Net Interest Coverage (Annual)-20.09x

EPS Basic Excl Extra (Annual)$1.43

P/FCF (TTM)2.78x

Receivables Turnover (TTM)1.14x

Total Debt / Equity (Quarterly)0.66x

EPS Incl Extra (TTM)$1.67

Receivables Turnover (Annual)0.65x

ROI (TTM)135.37%

P/S Ratio (TTM)5.23x

Pretax Margin (5Y Avg)-166.75%

Revenue / Share (Annual)$0.36

Tangible BV / Share (Annual)$0.12

Price vs S&P 500 (52W)70.05%

P/E Ratio (TTM)1.32x

EPS Growth TTM (YoY)735.87%

Year-to-Date Return11.97%

5-Day Price Return-1.24%

EPS Normalized (Annual)$1.43

ROA (5Y Avg)-13.87%

Net Profit Margin (Annual)398.43%

Month-to-Date Return-10.42%

Cash Flow / Share (TTM)$-2.49

EBITD / Share (Annual)$-1.51

Operating Margin (Annual)-429.51%

LT Debt / Equity (Annual)0.84x

ROI (5Y Avg)-6.87%

P/E Excl Extra (TTM)1.32x

LT Debt / Equity (Quarterly)0.66x

EPS Basic Excl Extra (TTM)$1.67

P/TBV (Quarterly)7.90x

P/B Ratio (Annual)2.81x

Inventory Turnover (TTM)3.59x

Pretax Margin (TTM)-368.28%

Book Value / Share (Annual)$0.50

Price vs S&P 500 (13W)-15.66%

Net Margin Growth (5Y)70.34%

Beta0.94x

P/FCF (Annual)1.67x

Revenue / Share (TTM)$0.34

ROE (TTM)214.57%

52-Week Low$0.71

vGradeB

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.25est. -0.28

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.17

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
CHRSCoherus Oncology, Inc. Common Stock	B	C	B	$1.57
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Coherus Oncology is a commercial-stage biotechnology company with LOQTORZI, an approved PD-1 inhibitor, and a pipeline of two mid-stage clinical candidates. The company is expanding LOQTORZI's use in nasopharyngeal cancer and exploring combination therapies with its pipeline candidates and industry partners. Key assets include LOQTORZI, CHS-114, and Casdozokitug, targeting liver, lung, head and neck, and other cancers.